Sigma Planning Corp Boosts Stake in Eli Lilly and Company $LLY

Sigma Planning Corp increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 7.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 18,320 shares of the company’s stock after purchasing an additional 1,260 shares during the quarter. Eli Lilly and Company accounts for 0.5% of Sigma Planning Corp’s portfolio, making the stock its 29th biggest holding. Sigma Planning Corp’s holdings in Eli Lilly and Company were worth $16,850,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp boosted its holdings in shares of Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Morgan Stanley grew its stake in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after acquiring an additional 407,166 shares during the period. Capital World Investors raised its holdings in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,154.27 on Wednesday. The stock has a market cap of $1.09 trillion, a P/E ratio of 41.00, a P/E/G ratio of 1.44 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The stock’s fifty day moving average is $1,106.93 and its 200 day moving average is $1,034.58. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 35.5 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LLY. Morgan Stanley raised their target price on shares of Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Royal Bank Of Canada increased their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Berenberg Bank raised their price target on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Finally, Guggenheim lifted their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,271.93.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly won full FDA approval for selpercatinib in solid tumors, a regulatory win that could support future oncology revenue and reinforces the strength of Lilly’s pipeline. Eli Lilly Wins Full FDA Approval for Selpercatinib in Solid Tumors
• Positive Sentiment: Wall Street sentiment remains constructive, with Guggenheim raising its price target on Lilly and maintaining a buy rating, while other recent reports highlighted bullish analyst views and momentum around the company’s pipeline. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with articles noting that its weight-loss drugs now account for a very large share of revenue, underscoring how central that growth engine remains for the stock. Here’s How Much Eli Lilly’s Weight-Loss Drugs Are Worth to Investors
• Neutral Sentiment: Lilly has been presenting new Kisunla data at the Alzheimer’s Association International Conference, which keeps attention on its dementia pipeline but does not yet appear to have delivered a clear market-moving surprise. Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades
• Neutral Sentiment: Commentary on whether Lilly’s shares can climb much higher has added to trading interest, but this is largely market speculation rather than a new fundamental catalyst. Is Lilly Stock On Track To Hit $2,090?
• Negative Sentiment: Despite the positive pipeline and analyst backdrop, traders are reacting to signs of weakness in LLY shares versus the broader market, suggesting some profit-taking or rotation out of the name. Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: One article flagged a “disturbing trend” in the billion-dollar obesity-drug market as Lilly prepares to roll out its new weight-loss pill, hinting at rising scrutiny of competition and execution risk in its most important growth category. Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.